Saturday, February 6, 2016

Dipexium reaches 75% enrolment in Phase 3 trials

Dipexium reaches 75% enrolment in Phase 3 trials

February 4, 2016 by · Leave a Comment 

Tweet Dipexium Pharmaceuticals’ (NASDAQ:DPRX) OneStep-1 and OneStep-2 pivotal Phase 3 clinical trials have reached the 75% enrollment milestone in total, with each study having enrolled nearly the same number of patients. OneStep-1 and OneStep-2 are identical Phase 3 trials, with 180 patients per clinical trial. They are being conducted under a SPA with the FDA […]

Leerink downgrades Carbylan to market perform

Leerink downgrades Carbylan to market perform

February 2, 2016 by · Leave a Comment 

Tweet Leerink Partners has downgraded Carbylan Therapeutics (NASDAQ:CBYL) to “market perform” from “outperform” and slashed its price target to $1.83 from $15 after the company reported a disappointing Phase 3 readout for Hydros-TA in the COR 1.1 trial. The shares were down 46% to $1.33 in after-market trading on Monday. The company’s lead program, Hydros-TA, […]

Knight to sublicense Titan Pharma’s Probuphine in Canada

Knight to sublicense Titan Pharma’s Probuphine in Canada

February 1, 2016 by · Leave a Comment 

Tweet Titan Pharmaceuticals’ (NASDAQ:TTNP) development and marketing partner, closely-held Braeburn Pharmaceuticals, and Knight Therapeutics (TSX:GUD) have entered into an agreement, giving Knight exclusive rights to commercialize Titan’s Probuphine in Canada. Probuphine is an investigational subdermal implant designed to deliver buprenorphine continuously for six months following a single treatment, promoting patient compliance and retention, as well […]

Rodman starts EyeGate Pharma at buy

Rodman starts EyeGate Pharma at buy

February 1, 2016 by · Leave a Comment 

Tweet Rodman & Renshaw has launched coverage of EyeGate Pharmaceuticals (NASDAQ:EYEG) with a “buy’ rating and a 12-month price target of $10. The stock closed at $1.70 on Friday. “In our view, the company’s EGP-437 combination product is differentiated from eye drops and intraocular injections in that it is non-invasive and solves patient non-compliance and […]

In conversation with Dr. Alan Schwebel

In conversation with Dr. Alan Schwebel

January 26, 2016 by · Leave a Comment 

Tweet As president and CEO of BioView (TASE:BIOV), Dr. Alan Schwebel has led the company, a world leader in automated fluorescence in situ hybridization (FISH) cell imaging and analysis, since 2009. Dr. Schwebel, who has more than 30 years of experience in senior management positions in leading medical device and medical diagnostic companies, joined BioView […]

Can-Fite receives patent notice for sexual dysfunction drug

Can-Fite receives patent notice for sexual dysfunction drug

January 19, 2016 by · Leave a Comment 

Tweet Can-Fite BioPharma (NYSE MKT:CANF; TASE:CFBI) has received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent titled, “A3 Adenosine Receptor Allosteric Modulators”. The composition of matter patent protects the use of Can-Fite’s proprietary A3 Adenosine Receptor (A3AR) modulator, including the preparation of its pharmaceutical compositions and its use in […]

EyeGate developing non-invasive ophthalmic treatments

EyeGate developing non-invasive ophthalmic treatments

January 19, 2016 by · Leave a Comment 

Tweet EyeGate Pharmaceuticals (NASDAQ:EYEG) is developing a non-invasive drug delivery platform that uses an electrical process, known as iontophoresis, to deliver a corticosteroid to the front-and back-of-the-eye for the treatment of ophthalmic conditions, such as anterior uveitis, macular edema and post-cataract surgery inflammation. “Our EyeGate II Delivery System addresses two of the most prevalent issues in […]

FDA adcom votes in favor of approving Titan’s Probuphine

FDA adcom votes in favor of approving Titan’s Probuphine

January 13, 2016 by · Leave a Comment 

Tweet The Psychopharmacologic Drugs Advisory Committee of the FDA voted 12-to-5 in favor of approving Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine, the first long-acting, subdermal buprenorphine implant for the maintenance treatment of opioid addiction, in stable patients receiving 8mg or less per day of buprenorphine. The committee’s vote followed presentation and discussion of data regarding Probuphine’s efficacy, safety, […]

Fibrocell translating personalized biologics into medical breakthroughs

Fibrocell translating personalized biologics into medical breakthroughs

January 12, 2016 by · Leave a Comment 

Tweet Fibrocell Science (NASDAQ:FCSC) is developing a pipeline of cell and gene therapies for localized treatment of connective tissue and joint diseases using autologous fibroblasts to deliver a targeted gene. “Our personalized biologics approach represents a dynamic new dimension to the field of cell therapy and regenerative medicine, aimed at treating the underlying cause of […]

Can-Fite unveils clinical milestones for 2016

Can-Fite unveils clinical milestones for 2016

January 11, 2016 by · Leave a Comment 

Tweet Can-Fite BioPharma (NYSE MKT:CANF; TASE:CFBI) has announced its anticipated clinical milestones for 2016. “We are very encouraged by the clinical and preclinical data from each of our drugs to date, which indicate their efficacy across six major indications,” CEO, Dr. Pnina Fishman, said in a statement. “We are moving towards initiating pivotal Phase 3 […]

Next Page »

Email Newsletters with Constant Contact
Google+